title: A convenient strategy for quantitative determination of drug concentrations in tissue homogenates using a liquid chromatography/tandem mass spectrometry assay for plasma samples.
abstract: Quantitative determination of drug concentrations in tissue homogenates via liquid chromatography-tandem mass spectrometry (LC-MS/MS) is commonly conducted using the standards and analytical quality controls (QCs) prepared in the same matrix (tissue homogenates), to keep the matrix and its effects consistent on the analytes during sample extraction and analysis. In this manuscript, we proposed to analyze tissue homogenate samples using an LC-MS/MS assay with the standards and analytical QCs prepared in plasma after tissue homogenate samples were appropriately diluted with plasma. BMS-650032 was used as a model compound, and its validated dog plasma assay was used for dog liver sample analyses. The tissue matrix effect was evaluated by diluting liver homogenate QCs with drug-free plasma at different dilution factors to determine the minimum required dilution factor (MRDF) at which tissue matrix has insignificant impact to the plasma assay. The percentage deviation of the measured concentration from the nominal concentration was used as an indicator of the tissue matrix effect. The results suggested that the tissue matrix effect was decreased as the plasma dilution factor increased. Based on the results of the tissue matrix effect evaluation, liver homogenate samples were analyzed after appropriate dilutions with plasma at the MRDF or greater dilution factors. The results confirmed that this approach generates accurate data, and the process is very convenient and economic. This approach has been used on the analyses of different tissues (liver and brain) and biofluid (bile) to support several drug development programs.
authors.affiliation: Analytical & Bioanalytical Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08540, United States.
authors.forename: Hao
authors.initials: H
authors.lastname: Jiang
authors.forename: Jianing
authors.initials: J
authors.lastname: Zeng
authors.forename: Naiyu
authors.initials: N
authors.lastname: Zheng
authors.forename: Hamza
authors.initials: H
authors.lastname: Kandoussi
authors.forename: Qianping
authors.initials: Q
authors.lastname: Peng
authors.forename: Jack L
authors.initials: JL
authors.lastname: Valentine
authors.forename: Robert W
authors.initials: RW
authors.lastname: Lange
authors.forename: Mark E
authors.initials: ME
authors.lastname: Arnold
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000097:blood* / Q000494:pharmacology; D002138:Calibration; D002853:Chromatography, Liquid / Q000379:methods*; D004283:Dog Diseases / Q000188:drug therapy / Q000821:virology; D004285:Dogs; D016174:Hepacivirus / Q000187:drug effects / Q000254:growth & development; D006526:Hepatitis C / Q000188:drug therapy / Q000821:virology; D008099:Liver / Q000737:chemistry*; D011786:Quality Control; D015203:Reproducibility of Results; D012107:Research Design; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D053719:Tandem Mass Spectrometry; D014020:Tissue Extracts / Q000032:analysis* / Q000737:chemistry
chemical_list: D000998:Antiviral Agents; D014020:Tissue Extracts